Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dual antiplatelet therapy is recommended after coronary stenting to prevent thrombotic complications, yet the benefits and risks of treatment beyond 1 year are uncertain. METHODS: Patients were enrolled after they had undergone a coronary stent procedure in which a drug-eluting stent was placed. After 12 months of treatment with a thienopyridine drug (clopidogrel or prasugrel) and aspirin, patients were randomly assigned to continue receiving thienopyridine treatment or to receive placebo for another 18 months; all patients continued receiving aspirin. The coprimary efficacy end points were stent thrombosis and major adverse cardiovascular and cerebrovascular events (a composite of death, myocardial infarction, or stroke) during the period from 12 to 30 months. The primary safety end point was moderate or severe bleeding. RESULTS: A total of 9961 patients were randomly assigned to continue thienopyridine treatment or to receive placebo. Continued treatment with thienopyridine, as compared with placebo, reduced the rates of stent thrombosis (0.4% vs. 1.4%; hazard ratio, 0.29 [95% confidence interval {CI}, 0.17 to 0.48]; P<0.001) and major adverse cardiovascular and cerebrovascular events (4.3% vs. 5.9%; hazard ratio, 0.71 [95% CI, 0.59 to 0.85]; P<0.001). The rate of myocardial infarction was lower with thienopyridine treatment than with placebo (2.1% vs. 4.1%; hazard ratio, 0.47; P<0.001). The rate of death from any cause was 2.0% in the group that continued thienopyridine therapy and 1.5% in the placebo group (hazard ratio, 1.36 [95% CI, 1.00 to 1.85]; P=0.05). The rate of moderate or severe bleeding was increased with continued thienopyridine treatment (2.5% vs. 1.6%, P=0.001). An elevated risk of stent thrombosis and myocardial infarction was observed in both groups during the 3 months after discontinuation of thienopyridine treatment. CONCLUSIONS: Dual antiplatelet therapy beyond 1 year after placement of a drug-eluting stent, as compared with aspirin therapy alone, significantly reduced the risks of stent thrombosis and major adverse cardiovascular and cerebrovascular events but was associated with an increased risk of bleeding. (Funded by a consortium of eight device and drug manufacturers and others; DAPT ClinicalTrials.gov number, NCT00977938.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, the reporting and interpretation of the risk of all-cause mortality in the DAPT (dual antiplatelet therapy) study randomizing 9,961 patients to continue DAPT beyond 1 y after stent placement or receive a placebo for 30 mo, raised some concerns (24, 25).”
From Misrepresentation and distortion of research in biomedical literature (2018) · cites this paper as [24]
In the citing paper
“Large observational studies or head-to-head RCTs show similar rates of gastrointestinal and non-gastrointestinal major bleeding for single antiplatelet therapy (SAPT) with low-dose ASA or a P2Y 12 inhibitor (clopidogrel or ticagrelor).”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [337]
In the citing paper
“Regarding CV safety, the composite of MI, stroke, CV death, CHD, and acute limb ischaemia was similar between pantoprazole and placebo, as was the rate of new-onset diabetes.”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [337]
In the citing paper
“Thus, gastrointestinal mucosal bleeding appears to be due to pre-existing mucosal lesions associated with defective primary haemostasis secondary to platelet inhibition, rather than with a specific antiplatelet drug.”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [337]
In the citing paper
“Combined antithrombotic drugs, while effective, increase major bleeding risk.337,338”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [337]
Citations
Cites
Statistical Analysis With Missing Data
Lahiff, M., Little, R. J. A., & Rubin, D. B. (1989) · Journal of the American Statistical Association · doi:10.2307/2289883 · Cited by 17,265
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Beaton, A. Z., Boehme, A. K., Buxton, A. E., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001123 · Cited by 8,300
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Self-citationPrasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
Self-citation(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions
Cutlip, D. E., Windecker, S., Mehran, R., Boam, A., Cohen, D. J., van Es, G.-A., Gabriel Steg, P., Morel, M.-A., Mauri, L., Vranckx, P., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.685313 · Cited by 5,497
Self-citationHeart Disease and Stroke Statistics—2013 Update: A Report From the American Heart Association
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., Fox, C. S., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31828124ad · Cited by 5,292
Mehran, R., Rao, S. V., Bhatt, D. L., Gibson, C. M., Caixeta, A., Eikelboom, J., Kaul, S., Wiviott, S. D., Menon, V., Nikolsky, E., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.009449 · Cited by 4,476
Self-citation(2014) · European Heart Journal · doi:10.1093/eurheartj/ehu278 · Cited by 4,314
Research works printed but not linked: 1
- Feres F, 2013, JAMA, 310, 2510
Cited by
Items 501–600 of 1,001
Howard, C. E., Nambi, V., Jneid, H. M., & Khalid, U. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012639 · Cited by 22
“However, there was no statistically significant difference in severe GUSTO or fatal bleeding.(2,5) As noted above, 2 of these 4 trials showed an improved primary efficacy end point of >24 months DAPT compared with standard 12-month DAPT, whereas the other 2 showed no difference.”
BackgroundResultInfluentialXie, J. X., Gunzburger, E. C., Kaun, L., Plomondon, M. E., Barón, A. E., Waldo, S. W., Virani, S. S., Maddox, T. M., & Mavromatis, K. (2019) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.118.005455 · Cited by 23
Cho, S., Kim, J., Kang, T. S., Hong, S., Shin, D., Ahn, C., Kim, B., Ko, Y., Choi, D., Song, Y. B., et al. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.10.046 · Cited by 22
Geng, X., Hussain, M., Du, H., Zhao, L., Chen, J., Su, W., Ma, L., Gao, Z., Ding, Y., & Ji, X. (2015) · Journal of Endovascular Therapy · doi:10.1177/1526602815579406 · Cited by 22
“The biggest retrospective analysis thus far found a 7% restenosis rate for first-generation DES over a follow-up period of 5 years.31 More recent reports support further improved restenosis rates when using mainly second-generation DES.32 Similarly, in an analysis of 28 consecutive patients presenting with symptomatic…”
ResultInfluentialRobbins, R., Tian, C., Singal, A. G., & Agrawal, D. (2015) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2015.03.1976 · Cited by 22
Dual Antiplatelet Therapy for Coronary Artery Disease
Lee, C. W. (2015) · Circulation Journal · doi:10.1253/circj.cj-14-1348 · Cited by 22
Costa, F., & Valgimigli, M. (2018) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2018.10.01 · Cited by 22
“Four trials compared the standard of care 12 months of DAPT, with a prolonged treatment duration for up to 18–48 months (Table 1) (22-25).”
BackgroundMethodBrener, S. J., Kirtane, A. J., Rinaldi, M. J., Stuckey, T., Witzenbichler, B., Weisz, G., Neumann, F., Metzger, D. C., Henry, T. D., Cox, D. A., et al. (2018) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.118.006853 · Cited by 21
Self-citationLi, Y., Jing, Q., Wang, B., Wang, X., Li, J., Qiao, S.-B., Chen, S., Angiolillo, D. J., & Han, Y. (2020) · American Heart Journal · doi:10.1016/j.ahj.2020.07.005 · Cited by 22
FILIPPO, O. D., Kang, J., Bruno, F., Han, J., Saglietto, A., Yang, H., Patti, G., Park, K. W., Parma, R., Kim, H.-S., et al. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2021.07.005 · Cited by 21
Pham, V., Moroni, A., Gall, E., Benedetti, A., Zivelonghi, C., & Picard, F. A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082833 · Cited by 28
“The results of the DAPT and Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction (PEGASUS-TIMI) 54 trials have endorsed the implementation of prolonged DAPT courses (beyond 12 months) in patients wi…”
MethodPlatelet Thrombin Receptor Antagonism With Vorapaxar: Pharmacology and Clinical Trial Development
Franchi, F., Rollini, F., Park, Y., & Angiolillo, D. J. (2015) · Future Cardiology · doi:10.2217/fca.15.50 · Cited by 21
Mahmud, E., Ramsis, M., Behnamfar, O., Enright, K., Huynh, A., Kaushal, K., Palakodeti, S., Li, S., Teh, P., Lin, F., et al. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.02.032 · Cited by 21
Impact of Optimal Medical Therapy in the Dual Antiplatelet Therapy Study
Resor, C. D., Nathan, A. S., Kereiakes, D. J., Yeh, R. W., Massaro, J. M., Cutlip, D. E., Steg, P. G., Hsieh, W.-H., & Mauri, L. (2016) · Circulation · doi:10.1161/circulationaha.116.024531 · Cited by 21
Self-citationLee, S. H., Yang, J. H., Choi, S., Park, T. K., Jang, W. J., Song, Y. B., Hahn, J., Choi, J., & Gwon, H. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176737 · Cited by 21
Optimal duration of dual antiplatelet therapy for coronary artery disease
Kikkert, W. J., & Damman, P. (2018) · Netherlands Heart Journal · doi:10.1007/s12471-018-1113-5 · Cited by 21
“9% absolute increase in GUSTO (global use of strategies to open occluded coronary arteries) moderate or severe bleeding [26].”
BackgroundKubica, J., Adamski, P., Niezgoda, P., Alexopoulos, D. K., Badarienė, J., Budaj, A., Buszko, K., Dudek, D., Fabiszak, T., Gąsior, M., et al. (2020) · Cardiology Journal · doi:10.5603/cj.a2020.0132 · Cited by 21
Alaaeddine, R. A., AlZaim, I., Hammoud, S. H., Arakji, A., Eid, A. H., Abd‐Elrahman, K. S., & EL‐Yazbi, A. F. (2021) · Clinical Science · doi:10.1042/cs20201445 · Cited by 21
Natsuaki, M., Morimoto, T., Shiomi, H., Kadota, K., Tada, T., Takeji, Y., Matsumura‐Nakano, Y., Yoshikawa, Y., Watanabe, H., Yamamoto, K., et al. (2021) · Circulation Journal · doi:10.1253/circj.cj-21-0016 · Cited by 21
Santoro, C., Capone, V., Canonico, M. E., Gargiulo, G., Esposito, R., Sanna, G. D., Parodi, G., & Esposito, G. (2021) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0041-1726298 · Cited by 21
Ideal P2Y12 Inhibitor in Acute Coronary Syndrome: A Review and Current Status
Pradhan, A. K., Tiwari, A., Caminiti, G., Salimei, C., Muscoli, S., Sethi, R., & Perrone, M. A. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19158977 · Cited by 22
Lu, R., Tang, F., Zhang, Y., Zhu, X., Zhu, S., Wang, G., Jiang, Y., & Fan, Z. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.003990 · Cited by 21
“The discontinuation of these agents leads to in-stent thrombosis and subsequent MI.(58) Moreover, data regarding medication, especially antiplatelet regimens, are limited, but the use of DESs typically follows a dual antiplatelet regimen that can increase the mortality rate in patients with coronary artery disease.”
BackgroundNishikawa, M., Takeda, Y., Isomura, N., Tanigawa, T., Nanasato, M., Tsukahara, K., Kimura, K., Takayama, T., Hirayama, A., Kato, M., et al. (2019) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.48934 · Cited by 22
Remnant Cholesterol: The Leftovers and Their Contribution to Atherosclerotic Cardiovascular Disease
Bruemmer, D., & Cho, L. (2021) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.121.012615 · Cited by 21
Brugaletta, S., Gori, T., Low, A. F.-H., Toušek, P., Pinar, E., Lara, J. G., Ortega‐Paz, L., Schulz, E., Chan, M. Y., Kočka, V., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.04.016 · Cited by 20
Regueiro, A., Cruz‐González, I., Bethencourt, A., y, L. N.-F., Champagne, J., Asmarats, L., Jiménez‐Quevedo, P., Gabella, T. R., Rama-Merchán, J. C., Puri, R., et al. (2018) · Journal of Interventional Cardiac Electrophysiology · doi:10.1007/s10840-018-0356-9 · Cited by 22
“It is well known that clopidogrel added to aspirin associates with a higher rate of bleeding complications than monotherapy [18, 19].”
BackgroundLüscher, T. F., Davies, A. J., Beer, J. H., Valgimigli, M., Nienaber, C. A., Camm, A. J., Baumgärtner, I., Diener, H., & Konstantinides, S. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab642 · Cited by 21
Report of the American Heart Association (AHA) Scientific Sessions 2014, Chicago
Kohno, T. (2014) · Circulation Journal · doi:10.1253/circj.cj-14-1329 · Cited by 21
Hudzik, B., Błachut, A., Lesiak, M., Kubica, J., Wojakowski, W., & Gąsior, M. (2022) · Kardiologia Polska · doi:10.33963/kp.a2022.0198 · Cited by 20
Trier, T. J. V., Snaterse, M., Hageman, S. H. J., ter Hoeve, N., Sunamura, M., van Charante, E. P. M., Galenkamp, H., Deckers, J. W., Martens, F. M. A. C., Visseren, F. L. J., et al. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad038 · Cited by 21
Tsoi, M. F., Cheung, C., Cheung, T. T., Wong, I. C. K., Kumana, C. R., Tse, H., & Cheung, B. M. Y. (2015) · Scientific Reports · doi:10.1038/srep13204 · Cited by 20
Antithrombotic therapy in peripheral artery disease
Foley, T. R., Waldo, S. W., & Armstrong, E. J. (2016) · Vascular Medicine · doi:10.1177/1358863x15622987 · Cited by 22
Park, Y., Franchi, F., Rollini, F., & Angiolillo, D. J. (2016) · Circulation Journal · doi:10.1253/circj.cj-16-0208 · Cited by 21
Bagai, A., Bhatt, D. L., Eikelboom, J. W., Mancini, G. B. J., Cohen, E. A., Vijayaraghavan, R., Cheema, A. N., Udell, J. A., Niznick, J., Tanguay, J., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.021158 · Cited by 21
Clinician's Guide to the Updated ABCs of Cardiovascular Disease Prevention: A Review Part 1
Arps, K. E., Pallazola, V. A., Cardoso, R. N., Meyer, J., Jones, R., Latina, J. M., Gluckman, T. J., Stone, N. J., Blumenthal, R. S., & McEvoy, J. W. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.01.016 · Cited by 22
Kang, J., Park, K. W., Ki, Y., Park, J., Rhee, T., Kim, C.-H., Han, J., Yang, H., Kang, H., Koo, B., et al. (2019) · Thrombosis and Haemostasis · doi:10.1055/s-0039-1688792 · Cited by 20
Self-citationDAPT Score and the Impact of Ticagrelor Monotherapy During the Second Year After PCI
Chichareon, P., Modolo, R., Kawashima, H., Takahashi, K., Kogame, N., Chang, C., Tomaniak, M., Ono, M., Walsh, S. J., Suryapranata, H., et al. (2020) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2019.12.018 · Cited by 20
“However, the rates of moderate or severe GUSTO bleeding and the BARC type 3 and 5 bleeding were comparable in the DAPT study (12).”
BackgroundMethodSelf-citationKuno, T., Ueyama, H. A., Takagi, H., Fox, J., & Bangalore, S. (2020) · Cardiovascular revascularization medicine · doi:10.1016/j.carrev.2020.07.039 · Cited by 20
Verdoia, M., Suryapranata, H., Damen, S. A. J., Camaro, C., Benit, E., Barbieri, L., Rasoul, S., Liew, H. B., Polad, J., Ahmad, W. A. W., et al. (2021) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-021-02439-x · Cited by 20
Chazova, I. E., Shestakova, M. V., Zhernakova, Y. V., Blinova, N. V., Маркова, Т. Н., Mazurina, N. V., Владиславович, Е. М., Tereshchenko, S. N., Жиров, И. В., Komarov, A. L., et al. (2021) · Eurasian heart journal · doi:10.38109/2225-1685-2021-2-6-61 · Cited by 25
Dohi, T., Maehara, A., Witzenbichler, B., Rinaldi, M. J., Mazzaferri, E. L., Duffy, P. L., Weisz, G., Neumann, F., Henry, T. D., Cox, D. A., et al. (2015) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.114.002447 · Cited by 20
Self-citationGrodzinsky, A., Arnold, S. V., Wang, T. Y., Sharma, P. K., GOSCH, K. L., Jones, P. G., Bhatt, D. L., Steg, P. G., McGuire, D. K., Cohen, D. J., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.09.010 · Cited by 21
Self-citationTatami, Y., Ishii, H., Aoki, T., Harada, K., Hirayama, K., Shibata, Y., Sumi, T., Negishi, Y., Kawashima, K., Kunimura, A., et al. (2017) · Circulation Journal · doi:10.1253/circj.cj-17-0015 · Cited by 20
Kang, D., Wee, S.-B., Ahn, J., Park, H., Yun, S.-C., Park, K., Kang, S. H., Suh, J., Bae, J., Park, S., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf652 · Cited by 19
Rohla, M., Weiss, T. W., Wojta, J., Niessner, A., & Huber, K. (2015) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvv014 · Cited by 24
Bundhun, P. K., Yanamala, C. M., & Huang, F. (2016) · BMC Cardiovascular Disorders · doi:10.1186/s12872-016-0343-y · Cited by 19
“PEGASUS [19], DAPT [20], Sardella2011 [21], PRODIGY [22], Thukkani2015 [23], ENDEAVOR [24], ITALIC [25]) that satisfied all the inclusion and exclusion criteria of this current analysis, were included.”
BackgroundLee, H., Koo, B., Park, K. W., Shin, E., Lim, S. W., Rha, S., Bae, J., Jeon, D. W., Oh, S.-K., Hur, S., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.12.001 · Cited by 19
“The necessity of trials providing strong evidence for the best antiplatelet monotherapy beyond DAPT after DES implantation During the last decade, PCI with DES has been established as the most effective strategy for CAD 22 Lee et al American Heart Journal March 2017 management by improving angina symptoms and reducing…”
BackgroundInfluentialRevisiting the role of durable polymers in cardiovascular devices
Mori, H., Otsuka, F., Gupta, A. K., Jinnouchi, H., Torii, S., Harari, E., Virmani, R., & Finn, A. V. (2017) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2017.1386098 · Cited by 19
“results of the DAPT trial which randomized patients receiving DES to 12 months versus 30 months of DAPT and examined ST and major adverse cardiovascular events[27].”
Moon, J. Y., Franchi, F., Rollini, F., & Angiolillo, D. J. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2018.1400378 · Cited by 19
“The DAPT (Dual Antiplatelet Therapy) trial [39] showed that prolonged DAPT (30 months of DAPT) was associated with a lower risk of ischemic events compared to 12-month DAPT.”
BackgroundPerera, K. S., Pearce, L. A., Sharma, M., Benavente, O., Connolly, S. J., & Hart, R. G. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.11.028 · Cited by 21
Nakahashi, T., Tada, H., Sakata, K., Nomura, A., Ohira, M., Mori, M., Takamura, M., Hayashi, K., Yamagishi, M., & Kawashiri, M. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.42317 · Cited by 20
Covic, A. C., Genovesi, S., Rossignol, P., Kalra, P. A., Ortíz, A., Banach, M., & Burlacu, A. (2018) · BMC Medicine · doi:10.1186/s12916-018-1145-0 · Cited by 19
Shimizu, A., Sonoda, S., Muraoka, Y., Setoyama, K., Inoue, K., Miura, T., Anai, R., Sanuki, Y., Miyamoto, T., Oginosawa, Y., et al. (2018) · Journal of Cardiology · doi:10.1016/j.jjcc.2018.12.009 · Cited by 19
Course of platelet miRNAs after cessation of P2Y12 antagonists
Jäger, B., Stojković, S., Haller, P. M., Piacková, E., Kahl, B. S., Andric, T., Vargas, K. G., Wojta, J., & Huber, K. (2019) · European Journal of Clinical Investigation · doi:10.1111/eci.13149 · Cited by 19
Floyd, C. N. (2020) · European Cardiology Review · doi:10.15420/ecr.2019.09 · Cited by 19
Hara, H., Klaveren, D. V., Takahashi, K., Kogame, N., Chichareon, P., Modolo, R., Tomaniak, M., Ono, M., Kawashima, H., Wang, R., et al. (2020) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.120.006660 · Cited by 19
Self-citationMihatov, N., Secemsky, E. A., Kereiakes, D. J., Steg, P. G., Serruys, P. W. J. C., Chichareon, P., Shen, C., & Yeh, R. W. (2020) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.29352 · Cited by 23
“the extension of DAPT therapy beyond 12-months in select patients has demonstrated a reduction in cardiovascular events at the cost of increased bleeding.(1-4) In parallel, randomized controlled trials (RCT)”
BackgroundSelf-citationLong‐Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS‐TIMI 54 Trial
Bergmark, B. A., Bhatt, D. L., Steg, P. G., Budaj, A., Storey, R. F., Gurmu, Y., Kuder, J., Im, K., Magnani, G., Ophuis, T. O., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.020446 · Cited by 19
Self-citationZhao, X., Li, J., Liu, F., Zhu, P., Jiang, L., Tang, X., Xu, J., Song, Y., Chen, J., Qiao, S., et al. (2021) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcab068 · Cited by 20
Bianco-Rondeau, M. D., Robert‐Halabi, M., Bloom, S., RABASA-LHORET, R. P. R., Tardif, J., Lordkipanidzé, M., & Marquis‐Gravel, G. (2022) · Thrombosis and Haemostasis · doi:10.1055/s-0042-1743469 · Cited by 19
Antithrombotics in stable peripheral artery disease
Kaplovitch, E., Rannelli, L., & Anand, S. S. (2019) · Vascular Medicine · doi:10.1177/1358863x18820123 · Cited by 21
Dual Antiplatelet Therapy after Drug-Eluting Stents — How Long to Treat?
Colombo, A., & Chieffo, A. (2014) · New England Journal of Medicine · doi:10.1056/nejme1413297 · Cited by 19
Duration of Dual Antiplatelet Therapy after Drug-Eluting Stents
Pfisterer, M., Kaiser, C., & Jeger, R. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1501195 · Cited by 19
Lemesle, G., Lamblin, N., Schurtz, G., Labreuche, J., Duhamel, A., Verdier, B., Steg, P. G., & Bauters, C. (2024) · Circulation · doi:10.1161/circulationaha.123.067938 · Cited by 18
Self-citationReport of the American Heart Association (AHA) Scientific Sessions 2015, Orlando
Aizawa, Y., Kimura, M., Kohno, T., Fujita, J., & Fukuda, K. (2015) · Circulation Journal · doi:10.1253/circj.cj-15-1272 · Cited by 18
Risk of cancer after an acute coronary syndrome according to the type of P2Y12 inhibitor
Raposeiras‐Roubín, S., Abu‐Assi, E., Muñoz‐Pousa, I., Fernández, M. C., Paz, R. C., Caneiro‐Queija, B., López-Rodríguez, E., Pérez-Casares, L., Jamhour-Chelh, K., Castiñeira-Busto, M., et al. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.12.014 · Cited by 18
Yin, D. R. P. P. C. P., & ten Berg, J. M. (2021) · Netherlands Heart Journal · doi:10.1007/s12471-021-01604-4 · Cited by 18
Personalized Approaches to Antiplatelet Treatment for Cardiovascular Diseases: An Umbrella Review
Oliva, A., Cao, D., Spirito, A., Nicolas, J., Pileggi, B., Kamaleldin, K. M., Vogel, B., & Mehran, R. (2023) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s391400 · Cited by 20
“26 Extended DAPT significantly reduced the incidence of MACE and stent thrombosis, but at the expense of increased bleeding and mortality.”
BackgroundState of the art: Oral antiplatelet therapy
Gurbel, P. A., Myat, A., Kubica, J., & Tantry, U. S. (2016) · JRSM Cardiovascular Disease · doi:10.1177/2048004016652514 · Cited by 22
“The underlying reason(s) for this observation remains unclear.(19) Thus, the results of DAPT and PEGASUS suggest prolonged therapy with more potent P2Y12 inhibitors without interruption in selected patients with high risk for ischemic events and lower risk for bleeding may be an option.”
BackgroundResultLee, S., Hong, M., Shin, D., Kim, J., Kim, B., Ko, Y., Choi, D., Jang, Y., Kim, H.-S., Valgimigli, M., et al. (2016) · Clinical Research in Cardiology · doi:10.1007/s00392-016-1035-4 · Cited by 18
“In addition, the DAPT study showed that both stent-related and non-stent-related myocardial infarctions were increased after the discontinuation of thienopyridine [13].”
Winter, M., Blessberger, H., Alimohammadi, A., Pávó, N., Huber, K., Wojta, J., Lang, I. M., Wiesbauer, F., & Goliasch, G. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.03.146 · Cited by 18
“Considering that young patients are per se at higher risk for recurrent ischemic events after ACS, it seems likely that they might benefit from a prolonged DAPT (as used in the DAPT trial) if they are diabetics [37].”
BackgroundHalim, H., Pinkaew, D., Chunhacha, P., Sinthujaroen, P., Thiagarajan, P., & Fujise, K. (2019) · PLoS ONE · doi:10.1371/journal.pone.0218934 · Cited by 18
“In the Dual Anti-Platelet Therapy (DAPT) study, Mauri et al. showed that DAPT beyond 1 year after placement of a drug-eluting stent (DES), as compared with ASA therapy alone, improved the cardiovascular outcomes of the patients with DES [20].”
The Combination of Oral Anticoagulant and Antiplatelet Therapies: Stay One Step Ahead
Lucà, F., Giubilato, S., Fusco, S. A. D., Leone, A., Poli, S., Rao, C. M., Iorio, A., Gelsomino, S., Gabrielli, D., Colivicchi, F., et al. (2020) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248420923528 · Cited by 19
“cardiovascular event (MACE), and recurrent MI with an increased risk of moderate or severe bleeding in the longterm DAPT arm.(13) Udell et al recently published a meta-analysis comprised of patients with previous MI from the PEGASUS, CHARISMA, PRODIGY, DES-LATE, ARTIC-Interruption and DAPT trials which evaluated the p…”
BackgroundZhu, H., Xu, X., Fang, X., Fei, Y., Song, L., Gao, B., Tong, G., Zhou, L., Chen, T., & Huang, J. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019184 · Cited by 18
Palmerini, T., Bruno, A. G., Redfors, B., Valgimigli, M., Taglieri, N., Feres, F., Abizaid, A., da Costa, R. A., Gilard, M., Morice, M., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.08.070 · Cited by 18
Sharma, A., Garg, A., Elmariah, S., Drachman, D. E., Obiagwu, C., Vallakati, A., Sharma, S. K., Lavie, C. J., Mukherjee, D., Waksman, R., et al. (2017) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2017.12.003 · Cited by 18
Han, Y. (2019) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000047 · Cited by 18
Said, S. A., Alabed, S., Kaier, K., Tan, A. R., Bode, C., Meerpohl, J. J., & Duerschmied, D. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013252.pub2 · Cited by 19
Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age
Joyce, L., Baber, U., Claessen, B. E. P. M., Sartori, S., Chandrasekhar, J., Cohen, D. J., Henry, T. D., Ariti, C. A., Dangas, G., Faggioni, M., et al. (2019) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2019.02.033 · Cited by 18
“potential beneficial effects of long-term DAPT must be compared to the increased risk of bleeding and subsequent increased risk of mortality (21-24).”
BackgroundSelf-citationGupta, S. K., Belley‐Côté, E. P., Panchal, P., Pandey, A. K., Basha, A., Pallo, L. P., Rochwerg, B. N., Mehta, S. R., Schwalm, J. D., & Whitlock, R. P. (2020) · Interactive Cardiovascular and Thoracic Surgery · doi:10.1093/icvts/ivaa115 · Cited by 18
Zhao, J., Huang, A., Zeller, J., Peter, K., & McFadyen, J. D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1256129 · Cited by 18
Linee guida ESC 2024 per la gestione delle sindromi coronariche croniche
Vrints, C. J., Andreotti, F., Koskinas, K. C., Rosselló, X., Adamo, M., Ainslie, J., BANNING, A. P., Budaj, A., Buechel, R. R., Chiariello, G. A., et al. (2024) · Giornale Ialiano di Cardiologia · doi:10.1714/4375.43725 · Cited by 18
P2Y12receptor inhibitors for secondary prevention of ischemic stroke
Liu, F., Tantry, U. S., & Gurbel, P. A. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1035256 · Cited by 18
Généreux, P., Redfors, B., Witzenbichler, B., Maehara, A., Yadav, M., Weisz, G., Francese, D. P., Parvataneni, R., Brener, S. J., Mehran, R., et al. (2016) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.26409 · Cited by 17
“A detailed sub-analysis of the recently published DAPT trial, which suggested that 30 months DAPT after DES implantation significantly reduced the risks of ST and major adverse ischemic events at the price of an increased risk of bleeding, could bring meaningful insight and help individualize treatment [40].”
BackgroundDual Antiplatelet Therapy After Drug-eluting Stent Implantation
Magnani, G., & Valgimigli, M. (2016) · Interventional Cardiology Reviews Research Resources · doi:10.15420/icr.2015:17:2 · Cited by 17
Elias, J., van Dongen, I. M., Kraak, R. P., Tijssen, R. Y. G., Claessen, B. E. P. M., Tijssen, J. G. P., de Winter, R. J., Piek, J. J., Wykrzykowska, J. J., & Henriques, J. P. S. (2017) · Netherlands Heart Journal · doi:10.1007/s12471-017-1008-x · Cited by 17
“This recommendation is supported by the results from the DAPT trial: treatment with metallic drug-eluting stents and DAPT beyond 1 year compared with aspirin alone was associated with a significantly reduced risk of stent thrombosis and cardiovascular events [29].”
ResultClinical implications of blood-material interaction and drug eluting stent polymers in review
Mori, H., Gupta, A. K., Torii, S., Harari, E., Jinnouchi, H., Virmani, R., & Finn, A. V. (2017) · Expert Review of Medical Devices · doi:10.1080/17434440.2017.1363646 · Cited by 17
“platelet agents [5] which are associated with increased risks of bleeding and overall higher mortality in some analyses [6].”
BackgroundChacko, Y., Parikh, R. V., & Tremmel, J. A. (2018) · Current Atherosclerosis Reports · doi:10.1007/s11883-018-0741-y · Cited by 17
Oral Antiplatelet Therapy for Secondary Prevention of Acute Coronary Syndrome
Berger, J. S. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-0291-2 · Cited by 18
Jäger, B., Piacková, E., Haller, P. M., Andric, T., Kahl, B. S., Christ, G., Geppert, A., Wojta, J., & Huber, K. (2019) · Archives of Medical Science · doi:10.5114/aoms.2018.81035 · Cited by 17
“However, the optimal duration of DAPT is an ongoing matter of debate [4] and distinct patients with high ischemic and low bleeding risk might benefit from extended DAPT [5].”
BackgroundResultMorici, N., Tavecchia, G., Antolini, L., Caporale, M. R., Cantoni, S., Bertuccio, P., Sacco, A., Meani, P., Viola, G., Brunelli, D., et al. (2019) · Angiology · doi:10.1177/0003319719848547 · Cited by 17
Validation of the DAPT score in real-world patients undergoing coronary stent implantation
Witberg, G., Zusman, O., Bental, T., Plakht, Y., Gabay, H., Gerber, Y., & Kornowski, R. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.08.044 · Cited by 17
Garg, A., Rout, A., Farhan, S., Waxman, S., Giustino, G., Tayal, R., Abbott, J. D., Huber, K., Angiolillo, D. J., & Rao, S. V. (2022) · American Heart Journal · doi:10.1016/j.ahj.2022.04.004 · Cited by 17
Simonsson, M., Alfredsson, J., Szummer, K. E., Jernberg, T., & Ueda, P. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.20030 · Cited by 17
Kozuki, A., Shinke, T., Otake, H., Kijima, Y., Masano, T., Nagoshi, R., Imamura, K., Fujiwara, R., Shibata, H., Takeshige, R., et al. (2015) · Journal of Cardiology · doi:10.1016/j.jjcc.2015.06.011 · Cited by 17
“In coronary artery disease management, DES dramatically reduced the incidence of in-stent restenosis; however, concerns about late stent thrombosis have emerged, and the adequate duration of dual anti-platelet therapy after DES implantation in coronary arteries remains controversial [4,5].”
BackgroundFanaroff, A. C., & Roe, M. T. (2016) · Drug Safety · doi:10.1007/s40264-016-0421-1 · Cited by 19
“recent clinical trials enrolling patients with stable CAD and PCI more than 12 months prior, the relatively modest benefit of extended-duration DAPT for the reduction of ischemic events has been offset by concerns about increases in bleeding complications with more aggressive antithrombotic therapy [14, 15].”
Ito, T. K., Derweesh, I., Ginzburg, S., Abbosh, P. H., Raheem, O. A., Mirheydar, H. S., Hamilton, Z. A., Chen, D. Y. T., Smaldone, M. C., Greenberg, R. E., et al. (2016) · The Journal of Urology · doi:10.1016/j.juro.2016.07.001 · Cited by 17
“Beyond 1 year, recent prospective trials suggest that maintaining DAPT for periods of up to several years after DES placement results in lower long-term rates of in-stent thrombosis and major cardiac or cerebrovascular events in patients able to tolerate the increased bleeding risk.(3,4) Given that approximately 20% o…”
BackgroundGuedeney, P., Aboyans, V., Dalon, F., Oksen, D., Belhassen, M., Nolin, M., Brière, J., Ganse, E. H. V., & Montalescot, G. (2019) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2019.05.009 · Cited by 17
Lohaus, R., Michel, J., Mayer, K., Lahmann, A. L., Byrne, R. A., Wolk, A., ten Berg, J. M., Neumann, F., Han, Y., Adriaenssens, T., et al. (2016) · Scientific Reports · doi:10.1038/srep33054 · Cited by 17
Implications of the PEGASUS-TIMI 54 trial for US clinical practice
Bradley, S. M., Hess, G. P., Stewart, P., Armstrong, E. J., Farmer, S. A., Wasfy, J. H., Valle, J. A., Sandhu, A., & Maddox, T. M. (2017) · Open Heart · doi:10.1136/openhrt-2016-000580 · Cited by 17
Metadata
- Authors
- Mauri, L., Kereiakes, D. J., Yeh, R. W., Driscoll-Shempp, P., Cutlip, D. E., Steg, P. G., Normand, S.-L. T., Braunwald, E., Wiviott, S. D., Cohen, D. J., Holmes, D. R., Krucoff, M. W., Hermiller, J., Dauerman, H. L., Simon, D. I., Kandzari, D. E., Garratt, K. N., Lee, D. P., Pow, T. K., Ver Lee, P., Rinaldi, M. J., & Massaro, J. M.
- Affiliations
- Brigham and Women's Hospital (US)
- Christ Hospital (US)
- Harvard University (US)
- Beth Israel Deaconess Medical Center (US)
- University of Missouri–Kansas City (US)
- Duke Medical Center (US)
- St Vincent Hospital (US)
- University of Vermont (US)
- University Hospitals Cleveland Medical Center (US)
- Piedmont Atlanta Hospital (US)
- Lenox Hill Hospital (US)
- Stanford University (US)
- Carolinas Healthcare System (US)
- Boston University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-12-04
- Volume
- 371
- Issue
- 23
- Pages
- 2155-2166
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4481318
- OpenAlex
- W2125173296
- Cited by
- 1,928
- References
- 39
- Citations by year
- 2026: 69 · 2025: 75 · 2024: 80 · 2023: 109 · 2022: 125 · 2021: 154 · 2020: 182 · 2019: 150 · 2018: 183 · 2017: 242 · 2016: 288 · 2015: 254 · 2014: 9
- FWCI
- 181.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- BORIS (University Library Bern) (submittedVersion, other-oa)
- Open Access CRIS of the University of Bern
- Funders
- U.S. Food and Drug Administration (1r01fd003870-01, R01 FD003870)
- National Heart, Lung, and Blood Institute (R01HL057506, R37HL057506, K23HL118138)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- dual antiplatelet therapy, drug-eluting stents, coronary stenting, clopidogrel, prasugrel, thienopyridines, aspirin, stent thrombosis, major adverse cardiovascular events, bleeding risk, myocardial infarction, stroke, mortality, periprocedural bleeding, bleeding risk stratification
- MeSH terms
- Prasugrel Hydrochloride, Clopidogrel, Aged, Aspirin, Drug Administration Schedule, Drug Therapy, Combination, Female, Hemorrhage, Humans, Male, Middle Aged, Piperazines, Platelet Aggregation Inhibitors, Thiophenes, Thrombosis, Ticlopidine, Time Factors, Incidence, Myocardial Ischemia, Drug-Eluting Stents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.